AIMS AND BACKGROUND: Recent clinical reports of stereotactic ablative radiotherapy (SABR) in the treatment of @entity263 have been encouraging. Our study evaluates the efficacy and safety of SABR using the CyberKnife system for treating intermediate- to very-high-risk @entity263 . METHODS AND STUDY DESIGN: Between May 2010 and June 2013, 31 @entity1 (15 intermediate risk, 14 high risk, and 2 very high risk) without pelvic lymph node @entity3 were enrolled retrospectively. The treatment consisted of 37.5 Gy in 5 fractions over 1-2 weeks using CyberKnife SABR. Twenty-five @entity1 (81%) received @entity342 deprivation therapy (ADT). Biochemical failure was defined using the nadir + 2 criterion. @entity137 was assessed with the Common Terminology Criteria of Adverse Events (version 4). RESULTS: The median follow-up was 36 months (range 7-58 months). The median pretreatment prostate--pecific antigen (PSA) was 13.5 ng/mL (range 4.5-124.0 ng/mL). The median PSA decreased to 0.09 ng/mL (range <0.04-5.38 ng/mL) and 0.12 ng/mL (range <0.04-2.63 ng/mL) at 6 months and 12 months after SABR, respectively. The 3-year biochemical relapse-free survival was 90.2% for all @entity1 , 100% for the intermediate-risk @entity1 , and 82% for the high- and very-high-risk @entity1 (p = 0.186). No @entity1 experienced >=  grade 3 @entity137 . There were 7 acute and 5 late grade 2 genitourinary @entity137 and 1 acute and no late grade 2 @entity344 . CONCLUSIONS: Our preliminary results support that CyberKnife SABR with ADT is safe and feasible in @entity1 with intermediate- to high-risk @entity263 . A further large-scale clinical trial with longer follow-up is warranted.

Stereotactic ablative radiotherapy with CyberKnife in the treatment of locally advanced XXXX : preliminary results.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity', 'toxicities'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer', 'low-risk prostate cancer'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal toxicity'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']
@entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']
